Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1470, 2005-01, pp. : 15-16
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Oxaliplatin plus irinotecan seems highly promising as a first-line treatment option
Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. :
Access to resources
Recommend
Docetaxel: clinical benefit in first-line treatment for NSCLC
Inpharma, Vol. 1, Iss. 1348, 2002-01 ,pp. :
By Méndez M. Alfonso P. Pujol E. González E. Castañon C. Cerezuela P. López-Mateos Y. Cruz J.
Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. :
Cisplatin + pemetrexed as first-line therapy for advanced NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. :
Cetuximab FLEXes muscle in first-line advanced NSCLC
Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. :